How I treat acute promyelocytic leukemia
- PMID: 19797519
- DOI: 10.1182/blood-2009-07-216457
How I treat acute promyelocytic leukemia
Abstract
Acute promyelocytic leukemia is the first malignant disease highly curable with targeted therapy directed at a unique molecular abnormality. The characteristic bleeding diathesis is the most notorious manifestation of the disease, which historically has accounted for a high mortality rate during induction. Acute promyelocytic leukemia is one of the few hematologic diseases that must be recognized under the microscope by the practicing hematologist because early institution of all-trans retinoic acid (ATRA) at the first suspicion of the disease before confirmation of the diagnosis and aggressive blood product support are critical to reduce early mortality. ATRA plus anthracycline-based chemotherapy for induction and consolidation followed by maintenance ATRA with low-dose chemotherapy is currently the standard of care. However, the combination of ATRA and arsenic trioxide, with minimal chemotherapy to control leukocytosis, is very effective therapy for newly diagnosed patients. This combination may replace conventional approaches for most, if not all, patients in the very near future. Acute promyelocytic leukemia should be considered in any patient with newly diagnosed acute myeloid leukemia because the treatment is urgent and different from all other subtypes.
Similar articles
-
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.Lancet Oncol. 2015 Oct;16(13):1295-305. doi: 10.1016/S1470-2045(15)00193-X. Epub 2015 Sep 14. Lancet Oncol. 2015. PMID: 26384238 Clinical Trial.
-
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).Blood. 2012 Aug 23;120(8):1570-80; quiz 1752. doi: 10.1182/blood-2012-02-410746. Epub 2012 Jun 19. Blood. 2012. PMID: 22715121 Clinical Trial.
-
Efficacy of prolonged therapy with combined arsenic trioxide and ATRA for relapse of acute promyelocytic leukemia.Haematologica. 2011 Sep;96(9):1390-1. doi: 10.3324/haematol.2011.045500. Epub 2011 Jun 9. Haematologica. 2011. PMID: 21659361 Free PMC article. No abstract available.
-
How to manage acute promyelocytic leukemia.Leukemia. 2012 Aug;26(8):1743-51. doi: 10.1038/leu.2012.57. Epub 2012 Mar 16. Leukemia. 2012. PMID: 22422168 Review.
-
Current treatment strategy of acute promyelocytic leukemia.Front Med. 2011 Dec;5(4):341-7. doi: 10.1007/s11684-011-0169-z. Epub 2011 Dec 27. Front Med. 2011. PMID: 22198746 Review.
Cited by
-
Triple-Negative Breast Cancer: Current Understanding and Future Therapeutic Breakthrough Targeting Cancer Stemness.Cancers (Basel). 2019 Sep 9;11(9):1334. doi: 10.3390/cancers11091334. Cancers (Basel). 2019. PMID: 31505803 Free PMC article. Review.
-
Case report: Purulent transformation of granulocytic sarcoma: An unusual pattern of differentiation in acute promyelocytic leukemia.Medicine (Baltimore). 2018 Feb;97(8):e9657. doi: 10.1097/MD.0000000000009657. Medicine (Baltimore). 2018. PMID: 29465554 Free PMC article.
-
Hyperfibrinolysis Is an Important Cause of Early Hemorrhage in Patients with Acute Promyelocytic Leukemia.Med Sci Monit. 2018 May 17;24:3249-3255. doi: 10.12659/MSM.909938. Med Sci Monit. 2018. PMID: 29771870 Free PMC article.
-
A Canadian consensus on the management of newly diagnosed and relapsed acute promyelocytic leukemia in adults.Curr Oncol. 2014 Oct;21(5):234-50. doi: 10.3747/co.21.2183. Curr Oncol. 2014. PMID: 25302032 Free PMC article.
-
Role of Retinoic Acid-Metabolizing Cytochrome P450s, CYP26, in Inflammation and Cancer.Adv Pharmacol. 2015;74:373-412. doi: 10.1016/bs.apha.2015.04.006. Epub 2015 May 27. Adv Pharmacol. 2015. PMID: 26233912 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical